Literature DB >> 1310071

FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.

O Aprelikova1, K Pajusola, J Partanen, E Armstrong, R Alitalo, S K Bailey, J McMahon, J Wasmuth, K Huebner, K Alitalo.   

Abstract

The receptors for at least two hematopoietic growth factors, namely the stem cell factor and colony-stimulating factor 1, belong to class III receptor tyrosine kinases. Here we describe cloning of a partial complementary DNA for FLT4, an additional member of this gene family from human leukemia cells. The FLT4 tyrosine kinase domain is 79% homologous with the previously cloned FLT1 (M. Shibuya et al., Oncogene, 5: 519-524, 1990) tyrosine kinase and maps to the chromosomal region 5q33-qter. We have found FLT4 expression in human placenta, lung, heart, and kidney, whereas the pancreas and brain appeared to contain very little if any FLT4 RNA. The results suggest that FLT4 functions in multiple adult tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310071

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.

Authors:  Xue-fen Wang; Ling-fang Tu; Li-hong Wang; Jian-ying Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-10       Impact factor: 3.066

Review 2.  Cardiovascular genomics: a current overview of in vivo and in vitro studies.

Authors:  Devi Mariappan; Johannes Winkler; Jürgen Hescheler; Agapios Sachinidis
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

3.  Genomic organization of the extracellular coding region of the human FGFR4 and FLT4 genes: evolution of the genes encoding receptor tyrosine kinases with immunoglobulin-like domains.

Authors:  F Agnès; M M Toux; C André; F Galibert
Journal:  J Mol Evol       Date:  1997-07       Impact factor: 2.395

4.  Proteolytic processing regulates receptor specificity and activity of VEGF-C.

Authors:  V Joukov; T Sorsa; V Kumar; M Jeltsch; L Claesson-Welsh; Y Cao; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

Review 5.  Scholars and scientists in the history of the lymphatic system.

Authors:  Gianfranco Natale; Guido Bocci; Domenico Ribatti
Journal:  J Anat       Date:  2017-06-14       Impact factor: 2.610

6.  Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas.

Authors:  E Hatva; T Böhling; J Jääskeläinen; M G Persico; M Haltia; K Alitalo
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

7.  Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains.

Authors:  D Rousset; F Agnès; P Lachaume; C André; F Galibert
Journal:  J Mol Evol       Date:  1995-10       Impact factor: 2.395

Review 8.  Lymphatics at the crossroads of angiogenesis and lymphangiogenesis.

Authors:  Claudio Scavelli; Elisabetta Weber; Margherita Aglianò; Teresa Cirulli; Beatrice Nico; Angelo Vacca; Domenico Ribatti
Journal:  J Anat       Date:  2004-06       Impact factor: 2.610

9.  Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.

Authors:  E Hatva; A Kaipainen; P Mentula; J Jääskeläinen; A Paetau; M Haltia; K Alitalo
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

10.  The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.

Authors:  M Sandström; M Johansson; U Andersson; A Bergh; A T Bergenheim; R Henriksson
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.